Sun Pharma leads the sector with the highest market capitalization and strong investor confidence.
Mankind Pharma and Laurus Labs delivered impressive short-term returns with rising market attention.
Cipla, Dr. Reddy's, and Zydus offer comparatively lower PE ratios with stable business strength.
The Indian pharmaceutical sector has great potential as the demand for medicine and healthcare support remains high. Big pharma firms earn decent revenue from exports, specialty drugs, hospitals, and research work. Many investors now consider pharma shares for stable long-term wealth. Some companies like Sun Pharmaceutical and Mankind Pharma have offered solid returns in recent months and also hold strong market value.
Below are some of the top pharmaceutical stocks that may stay important for long-term investment plans.
Sun Pharmaceutical is the largest pharma company in India by market value. The stock price is at Rs. 1,883.00 with a 1.90% rise. The company holds a massive market cap of Rs. 4,51,795 crore. Its PE ratio is 40.18, while the industry PE is 29.45.
The stock touched a 52-week high of Rs. 1,857.80 and a low of Rs. 1,548.00. It booked a one-month return of 9.82%, while the three-month return reached 11.08%. These numbers show strong investor trust. Sun Pharma also has a strong global business and a wide medicine portfolio, which offers balance during market volatility.
Divis Laboratories is one of the most respected pharma firms in India. The share price stands at Rs. 6,755.50 with a 0.67% rise. The market cap is strong at Rs. 1,79,337 crore. The PE ratio is 71.76, while the industry PE stays at 33.59.
The stock reached a 52-week high of Rs. 7,071.50 and a low of Rs. 5,636.50. The firm delivered a one-month return of 14.85% while the three-month return touched 12.13%. Divis Laboratories focuses on high-quality active pharmaceutical ingredients and export business. Many investors view this company as a premium pharma stock for long-term growth.
Also Read - Best Low-Price Stocks Under Rs. 30 in India for 2026
Torrent Pharmaceuticals’ stock price stands at Rs. 4,483.70 with a 2.35% gain. The company holds a market cap of Rs. 1,51,749 crore. The PE ratio is 64.93 while the industry PE stands at 31.62.
The 52-week high came at Rs. 4,482.90 while the low reached Rs. 3,101.60. The stock booked a one-month return of 11.28% and a three-month return of 13.83%. Torrent Pharma has a strong presence in heart care, diabetes, and chronic treatment areas. This helps the company maintain stable earnings.
Cipla is one of the oldest and most-trusted pharma brands in India. The stock is currently trading at Rs. 1,338.00 with a small decline of 0.67%. The company's market cap stays at Rs. 1,08,081 crore, with a PE ratio of 24.28.
The stock touched a 52-week high of Rs. 1,673.00 and a low of Rs. 1,165.70. It offered a one-month return of 10.04% and a three-month return of 0.60%. Cipla earns strong trust because of its respiratory products and global healthcare business. Many investors prefer Cipla because of its stable nature and reasonable valuation.
Dr. Reddy's Laboratories continues to attract long-term investors. The current market price of the stock is Rs. 1,290.90 with a small decline of 0.23%. The company's market cap is Rs. 1,07,744 crore, with a PE ratio of 19.75.
The stock reached a 52-week high of Rs. 1,379.70 and a low of Rs. 1,138.50. The one-month return came at 8.35% while the three-month return reached 4.00%. The company’s strong export market and generic medicine business provide stable revenue support.
Lupin experienced pressure in recent sessions, but it still remains an important pharma player. The stock price stands at Rs. 2,251.10 with a 5.40% decline. The company has a market cap of Rs. 1,02,885 crore and a PE ratio of 24.09.
The stock touched a 52-week high of Rs. 2,494.00 and a low of Rs. 1,836.80. It booked a loss of 1.87% in a month and a profit of 3.56% in three months. Lupin has a strong business in respiratory and generic medicines. Many investors may watch this stock for recovery chances.
Mankind Pharma’s current market price is Rs. 2,436.70 with a 0.24% rise. The company's market cap is at Rs. 1,00,588 crore with a PE ratio of 54.38.
The stock reached a 52-week high of Rs. 2,716.50 and a low of Rs. 1,909.70. The firm delivered a one-month return of 19.33% while the three-month return reached 18.27%. These numbers show strong momentum. Mankind Pharma has a powerful domestic medicine business and a wide product reach across India.
Zydus Life Science is a strong pharma stock with a CMP of Rs. 943.25 and a 0.34% rise. The market cap stays at Rs. 94,913 crore, while the PE ratio remains at 18.82.
The stock touched a 52-week high of Rs. 1,059.05 and a low of Rs. 835.50. The one-month return came at 5.80% while the three-month return reached 6.20%. Zydus offers long-term growth support through continuous expansion in specialty medicines and global markets.
Also Read - Best Stocks for Long-Term Investment in May 2026
Aurobindo Pharma shows steady performance with a trading price of Rs. 1,493.80 and a 0.44% rise. The company's market cap is Rs. 86,760 crore, and the PE ratio is 24.64.
The stock reached a 52-week high of Rs. 1,513.40 and a low of Rs. 1,016.10. It recorded a profit of 11.84% and 25.42% in one and three months, respectively. This strong performance in the recent months shows growing investor confidence. The company also has a major export business and a strong generic drug portfolio.
Laurus Labs also gained attention from investors. The stock price stands at Rs. 1,266.90 with a 3.14% rise. The company's market cap is Rs. 68,394 crore, and a PE ratio of 73.16.
The stock touched a 52-week high of Rs. 1,237.90 and a low of Rs. 572.25. The one-month return came at 17.04% while the three-month return reached 33.28%. Laurus Labs has strong business in APIs and specialty products. High returns in recent months show strong market interest.
The pharmaceutical sector may continue to grow with healthcare demand, exports, and new medicine development. Large companies with stable earnings and strong global business may offer better safety for long-term investors. Investors who look for growth and stability may keep these pharma stocks on their watchlist.
Which pharma stock has the highest market cap?
Sun Pharmaceutical Industries has the highest market capitalization at approximately Rs. 4,51,795 crore, making it one of the largest pharmaceutical companies in India. Its strong domestic presence, global operations, and diversified product portfolio contribute significantly to its market leadership.
Which pharma stock gave the best 3-month return?
Laurus Labs delivered the highest 3-month return of 33.28%, supported by improving business performance and positive investor sentiment. Strong demand in select segments, export opportunities, and financial growth helped drive the stock’s short-term gains.
Which stock looks cheaper based on PE ratio?
Zydus Lifesciences and Dr. Reddy's Laboratories appear relatively cheaper based on their lower price-to-earnings (PE) ratios compared to several peers. Lower PE ratios may indicate better valuation opportunities, though company performance and growth prospects also matter.
Why do investors prefer pharma stocks?
Investors often prefer pharma stocks because healthcare demand remains relatively stable regardless of economic conditions. Pharmaceutical companies benefit from continuous medicine demand, export opportunities, innovation in treatments, and growing healthcare needs driven by aging populations and lifestyle diseases.
Are pharma stocks suitable for long-term investment?
Many investors consider pharma stocks suitable for long-term investment due to consistent healthcare demand and global expansion opportunities. Strong research capabilities, export growth, and increasing spending on healthcare can support steady business performance and long-term wealth creation.
Join our WhatsApp Channel to get the latest news, exclusives and videos on WhatsApp
_____________
Disclaimer: Analytics Insight does not provide financial advice or guidance on cryptocurrencies and stocks. Also note that the cryptocurrencies mentioned/listed on the website could potentially be risky, i.e. designed to induce you to invest financial resources that may be lost forever and not be recoverable once investments are made. This article is provided for informational purposes and does not constitute investment advice. You are responsible for conducting your own research (DYOR) before making any investments. Read more about the financial risks involved here.